Evaluation of the peri-strut low intensity area following sirolimus- and paclitaxel-eluting stents implantation: insights from an optical coherence tomography study in humans

Int J Cardiol. 2012 May 17;157(1):38-42. doi: 10.1016/j.ijcard.2010.11.006. Epub 2010 Dec 18.

Abstract

Background: Recent pathological studies have demonstrated that peri-strut low intensity area (PLIA) seen on optical coherence tomography (OCT) imaging represents the presence of fibrinogen and/or extracellular matrix. We sought to assess the clinical prevalence of PLIA and its relation to neointimal proliferation after the implantation of sirolimus- (SES) and paclitaxel-eluting stents (PES) in humans.

Methods: Seventy patients underwent 6-months follow-up OCT after SES (43 stents) or PES (37 stents) implantation. PLIA was defined as a region around stent struts with homogenous lower intensity than surrounding tissue on OCT images without signal attenuation. The incidence of stent struts with PLIA (+PLIA struts) was calculated as the number of +PLIA struts/number of all struts (%).

Results: PES showed a higher incidence of stents with PLIA than SES (86% vs. 58%; p=0.005) with a higher prevalence of +PLIA struts (27.8±21.9% vs. 10.9±11.0%; p=0.0008). SES with PLIA showed a significantly greater neointimal thickness (NIT) than SES without PLIA (p=0.02), while PES showed a similar tendency (p=0.19). In a detailed strut basis analysis, average NIT on +PLIA struts were significantly greater than that on -PLIA struts in both SES and PES. In addition, average NIT was positively correlated with the prevalence of +PLIA struts (SES: Rho=0.73; p<0.0001, PES: Rho=0.58, p=0.0005) in both stents.

Conclusions: The prevalence of PLIA was significantly higher in PES than in SES. The presence and extent of PLIA might be associated with intimal thickening after 1st-generation DES implantation.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Coronary Artery Disease / diagnostic imaging
  • Coronary Artery Disease / drug therapy
  • Drug-Eluting Stents / standards*
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Neointima / diagnostic imaging*
  • Neointima / drug therapy*
  • Paclitaxel / administration & dosage*
  • Radiography
  • Retrospective Studies
  • Sirolimus / administration & dosage*
  • Tomography, Optical Coherence / methods
  • Tomography, Optical Coherence / standards*
  • Treatment Outcome

Substances

  • Paclitaxel
  • Sirolimus